Evinova China and Harbour BioMed Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, and Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, announced a strategic collaboration in artificial intelligence (AI).

Under the terms of the collaboration, Evinova China and Harbour BioMed will jointly apply AI and digital technologies to enhance the efficiency of innovative biologics development. Building on their own strengths, the two companies aim to build an open ecosystem for AI-driven drug R&D.

Nate Zhang, General Manager of Evinova China, stated, “Evinova leverages the digital transformation insights of top global pharmaceutical companies to design our AI-powered clinical development solutions and digital strategy consulting services, so that we can accelerate the delivery of better health outcome s. To realize our mission, Evinova China needs to partner with innovative companies like Harbour BioMed, which are rooted in China while harboring global ambitions. Together, through our world-class AI technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world.”

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated, “We are pleased to collaborate with Evinova to advance the application of AI in biotherapeutic development. Harbour BioMed has built a robust and differentiated product pipeline based on our industry-leading Harbour Mice® technology platform. Through this collaboration, we look forward to applying AI to improving clinical study efficiency and accelerating the delivery of innovative therapies to patients around the world.”